Lisata Therapeutics (NASDAQ:LSTA) Rating Lowered to Hold at Brookline Capital Management

Lisata Therapeutics (NASDAQ:LSTA) was downgraded by research analysts at Brookline Capital Management from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, MarketBeat reports.

LSTA has been the subject of a number of other research reports. Zacks Research lowered Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lisata Therapeutics presently has an average rating of “Hold” and a consensus price target of $23.50.

Lisata Therapeutics Stock Up 0.7%

Lisata Therapeutics stock opened at $4.06 on Wednesday. The firm has a fifty day moving average of $2.11 and a 200-day moving average of $2.35. Lisata Therapeutics has a 52-week low of $1.81 and a 52-week high of $4.17. The firm has a market capitalization of $35.81 million, a P/E ratio of -1.91 and a beta of 1.11.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. On average, research analysts expect that Lisata Therapeutics will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Ground Swell Capital LLC bought a new stake in shares of Lisata Therapeutics during the 3rd quarter valued at about $62,000. CIBC Bancorp USA Inc. acquired a new position in Lisata Therapeutics in the third quarter valued at approximately $37,000. Finally, Cerity Partners LLC bought a new position in shares of Lisata Therapeutics during the second quarter valued at approximately $32,000. 8.94% of the stock is owned by institutional investors and hedge funds.

More Lisata Therapeutics News

Here are the key news stories impacting Lisata Therapeutics this week:

• Positive Sentiment: Kuva Labs agreed to a tender offer of $4.00 per share in cash and two CVRs (each $1.00) tied to milestones — the offer represents roughly an 85% premium to Lisata’s recent price and ~180% including CVRs, and both boards have unanimously approved the term sheet. GlobeNewswire: Acquisition Term Sheet
• Positive Sentiment: Market outlets report a strong intraday spike and heavy coverage after the offer — headlines highlight the steep premium and near-term upside to holders if the deal completes. Investing.com: Stock Soars After Offer
• Neutral Sentiment: Trading in LSTA was temporarily halted for “news pending” ahead of the announcement, which is typical around material M&A disclosures and can cause short-term volatility once resumed.
• Neutral Sentiment: Analyses and feature stories are re-pricing Lisata’s outlook, quantifying how the offer and CVRs reshape valuation assumptions for its lead candidate, certepetide — useful context for investors weighing tender vs. hold. Yahoo Finance: Valuation Outlook
• Negative Sentiment: Brookline Capital downgraded Lisata from “Buy” to “Hold,” signaling some sell-side caution on upside beyond the offer or on deal execution/terms. MSN: Brookline Capital Downgrade
• Negative Sentiment: An investor-rights law firm, Halper Sadeh LLC, has opened an investigation into whether the proposed sale is fair to shareholders (noting the CVRs are non-tradeable and contingent) — potential litigation or proxy/tender complications could delay or alter deal terms. BusinessWire: Investigation Notice

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.